In the case of formulations under development for indications such as pain management, migraine, seizure and biologics such as vaccines, which require a delivery system with precision control over spray plume geometry and deposition to the nasal mucosa for systemic uptake, pharmaceutical manufacturers have turned their attention to unit-dose, aseptic intranasal drug products. This type of delivery system for intranasal drugs presents challenges due to the cost and difficulty of aseptic packaging of the drug and device components. However, a new development in unit-dose aseptic packaging based on a novel Form Fill Seal (FFS) technology is showing great promise as a cost-effective alternative.
Unit-dose aseptic packaging of nasal drugs
Development of new Form Fill Seal technology offers significant economic and functional benefits to aseptic packaging and delivery of intranasal drug products.